Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
85 Pages - GMD12053
$2,000.00

Summary

Global Markets Direct’s, ‘Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H1 2014’, provides an overview of the Relapsing Multiple Sclerosis (RMS)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsing Multiple Sclerosis (RMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Multiple Sclerosis (RMS) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Relapsing Multiple Sclerosis (RMS)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Relapsing Multiple Sclerosis (RMS) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Relapsing Multiple Sclerosis (RMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Relapsing Multiple Sclerosis (RMS) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Relapsing Multiple Sclerosis (RMS)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Relapsing Multiple Sclerosis (RMS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Relapsing Multiple Sclerosis (RMS) Overview 8
Therapeutics Development 9
Pipeline Products for Relapsing Multiple Sclerosis (RMS) - Overview 9
Pipeline Products for Relapsing Multiple Sclerosis (RMS) - Comparative Analysis 10
Relapsing Multiple Sclerosis (RMS) - Therapeutics under Development by Companies 11
Relapsing Multiple Sclerosis (RMS) - Therapeutics under Investigation by Universities/Institutes 13
Relapsing Multiple Sclerosis (RMS) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Relapsing Multiple Sclerosis (RMS) - Products under Development by Companies 17
Relapsing Multiple Sclerosis (RMS) - Products under Investigation by Universities/Institutes 18
Relapsing Multiple Sclerosis (RMS) - Companies Involved in Therapeutics Development 19
F. Hoffmann-La Roche Ltd. 19
Biogen Idec Inc. 20
Sanofi 21
Apitope International NV 22
Octapharma AG 23
to-BBB technologies BV 24
Meiji Seika Pharma Co., Ltd. 25
BIOCAD 26
Relapsing Multiple Sclerosis (RMS) - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
peginterferon beta-1a - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
alemtuzumab - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ocrelizumab - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
minocycline - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
immune globulin (human) - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Epigallocatechin Gallate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BIIB-033 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
natalizumab - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ATX-1467 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
2B3-201 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
interferon beta-1a - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CP-9531 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Relapsing Multiple Sclerosis (RMS) - Recent Pipeline Updates 59
Relapsing Multiple Sclerosis (RMS) - Dormant Projects 73
Relapsing Multiple Sclerosis (RMS) - Discontinued Products 74
Relapsing Multiple Sclerosis (RMS) - Product Development Milestones 75
Featured News & Press Releases 75
Jan 06, 2014: Receptos Begins Enrollment of Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis 75
Oct 03, 2013: Real-world evidence showed superiority of Novartis' Gilenya to reduce MS relapse rates compared to interferons or glatiramer acetate 75
Oct 03, 2013: Teva to Present Further Results of Twenty-Year Open-Label Extension Study of Glatiramer Acetate 20 mg Daily for Relapsing-Remitting Multiple Sclerosis 76
Oct 01, 2013: New Data Analyses Show Significant Clinical and MRI Improvements with PLEGRIDY 77
Sep 03, 2013: Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis 78
Jul 19, 2013: US and EU Regulatory Authorities Accept PLEGRIDY Marketing Applications for Review 79
Jun 05, 2013: RedHill Biopharma Commences Patient Screening In Phase IIa Clinical Trial With RHB-104 For Multiple Sclerosis 80
Jun 05, 2013: Receptos Provides Update On Progress Of Lead Product Candidate RPC1063 80
May 30, 2013: Teva Announces FDA Acceptance Of sNDA For Higher Concentration Dose Of Copaxone 82
May 21, 2013: Biogen Idec Submits Application To FDA For Approval Of Plegridy In Multiple Sclerosis 82
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 85
Disclaimer 85

List of Tables
Number of Products under Development for Relapsing Multiple Sclerosis (RMS), H1 2014 9
Number of Products under Development for Relapsing Multiple Sclerosis (RMS) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Relapsing Multiple Sclerosis (RMS) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 19
Relapsing Multiple Sclerosis (RMS) - Pipeline by Biogen Idec Inc., H1 2014 20
Relapsing Multiple Sclerosis (RMS) - Pipeline by Sanofi, H1 2014 21
Relapsing Multiple Sclerosis (RMS) - Pipeline by Apitope International NV, H1 2014 22
Relapsing Multiple Sclerosis (RMS) - Pipeline by Octapharma AG, H1 2014 23
Relapsing Multiple Sclerosis (RMS) - Pipeline by to-BBB technologies BV, H1 2014 24
Relapsing Multiple Sclerosis (RMS) - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2014 25
Relapsing Multiple Sclerosis (RMS) - Pipeline by BIOCAD, H1 2014 26
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 30
Number of Products by Stage and Mechanism of Action, H1 2014 33
Number of Products by Stage and Route of Administration, H1 2014 35
Number of Products by Stage and Molecule Type, H1 2014 37
Relapsing Multiple Sclerosis (RMS) Therapeutics - Recent Pipeline Updates, H1 2014 59
Relapsing Multiple Sclerosis (RMS) - Dormant Projects, H1 2014 73
Relapsing Multiple Sclerosis (RMS) - Discontinued Products, H1 2014 74

List of Figures
Number of Products under Development for Relapsing Multiple Sclerosis (RMS), H1 2014 9
Number of Products under Development for Relapsing Multiple Sclerosis (RMS) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 31
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 32
Number of Products by Top 10 Route of Administration, H1 2014 34
Number of Products by Stage and Top 10 Route of Administration, H1 2014 35
Number of Products by Top 10 Molecule Type, H1 2014 36
Number of Products by Stage and Top 10 Molecule Type, H1 2014 37

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax